Form 4 holding
Director
SHERWIN WILLIAMS CO
- Security class
- Common Stock
- Shares / value
- 12,386
- Estimated value
- $4,189,565
- Report date
- 04 Apr 2025
- Price
- $338.25
- Ownership
- Direct
Christine A. Poon
Insider Reports History
- Reporting-owner location
- New Brunswick, NJ
- Latest reporting-owner signature
-
/s/ Danny Fiore, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Christine A. Poon
Form 4 holding
Director
REGENERON PHARMACEUTICALS, INC.
- Security class
- Common Stock
- Shares / value
- 5,219
- Estimated value
- $4,028,389
- Report date
- 02 Jan 2026
- Price
- $771.87
- Ownership
- Direct
Form 4 holding
Director
PRUDENTIAL FINANCIAL INC
- Security class
- Notional Shares - Mandatory
- Shares / value
- 13,679
- Estimated value
- $1,556,647
- Report date
- 11 Jun 2026
- Price
- $117.05
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
PRUDENTIAL FINANCIAL INC
- Security class
- Common Stock
- Shares / value
- 11,583
- Estimated value
- $1,131,543
- Report date
- 12 May 2026
- Price
- $97.69
- Ownership
- Direct
Form 4 holding
Director
SHERWIN WILLIAMS CO
- Security class
- Common Stock
- Shares / value
- 2,573
- Estimated value
- $870,446
- Report date
- 04 Apr 2025
- Price
- $338.25
- Ownership
- Deferred Fee Plan
Form 4 holding
Director
NEUROCRINE BIOSCIENCES INC
- Security class
- Common Stock
- Shares / value
- 4,753
- Estimated value
- $626,160
- Report date
- 21 May 2026
- Price
- $131.74
- Ownership
- Direct
Form 4 holding
Director
PRUDENTIAL FINANCIAL INC
- Security class
- Notional Shares - Optional
- Shares / value
- 4,198
- Estimated value
- $477,798
- Report date
- 11 Jun 2026
- Price
- $117.05
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
NEUROCRINE BIOSCIENCES INC
- Security class
- Non-Qualified Stock Option
- Shares / value
- 2,982
- Estimated value
- $219,475
- Report date
- 22 May 2024
- Price
- $73.60
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
NEUROCRINE BIOSCIENCES INC
- Security class
- Restricted Stock Unit
- Shares / value
- 1,435
- Estimated value
- $203,629
- Report date
- 22 May 2024
- Price
- $141.90
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
PRUDENTIAL FINANCIAL INC
- Security class
- 2025 Restricted Stock Units
- Shares / value
- 0
- Estimated value
- $203,432
- Report date
- 12 May 2026
- Price
- $117.05
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
PRUDENTIAL FINANCIAL INC
- Security class
- 2024 Restricted Stock Units
- Shares / value
- 0
- Estimated value
- $138,758
- Report date
- 13 May 2025
- Price
- $105.04
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
NEUROCRINE BIOSCIENCES INC
- Security class
- Restriced Stock Unit
- Shares / value
- 2,567
- Estimated value
- Report date
- 27 May 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
REGENERON PHARMACEUTICALS, INC.
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 1,962
- Estimated value
- Report date
- 02 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
PRUDENTIAL FINANCIAL INC
- Security class
- 2026 Restricted Stock Units
- Shares / value
- 1,777
- Estimated value
- Report date
- 11 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
NEUROCRINE BIOSCIENCES INC
- Security class
- Restricted Stock Unit
- Shares / value
- 0
- Estimated value
- Report date
- 21 May 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Christine A. Poon
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 11 Jun 2026
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2026, 14:28
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 27 May 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 May 2026, 18:03
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 21 May 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 21 May 2026, 19:22
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 12 May 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 14 May 2026, 12:47
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 12 Mar 2026
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 16 Mar 2026, 14:56
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 02 Jan 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2026, 16:03
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 11 Dec 2025
- Transactions
- 3
- Transaction value
- +$25,283
- Accepted by SEC
- 15 Dec 2025, 17:34
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 29 Oct 2025
- Transactions
- 10
- Transaction value
- +$537,587
- Accepted by SEC
- 31 Oct 2025, 16:09
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 11 Sep 2025
- Transactions
- 3
- Transaction value
- +$25,036
- Accepted by SEC
- 12 Sep 2025, 15:41
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 12 Jun 2025
- Transactions
- 3
- Transaction value
- +$24,652
- Accepted by SEC
- 16 Jun 2025, 16:19
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 21 May 2025
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 22 May 2025, 17:32
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 13 May 2025
- Transactions
- 4
- Transaction value
- -$141,875
- Accepted by SEC
- 15 May 2025, 17:08
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 04 Apr 2025
- Transactions
- 1
- Transaction value
- +$1,390
- Accepted by SEC
- 07 Apr 2025, 16:37
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 13 Mar 2025
- Transactions
- 3
- Transaction value
- +$23,844
- Accepted by SEC
- 17 Mar 2025, 15:54
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 18 Feb 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 Feb 2025, 17:09
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 03 Jan 2025
- Transactions
- 1
- Transaction value
- +$8,439
- Accepted by SEC
- 07 Jan 2025, 19:10
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 02 Jan 2025
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2025, 16:07
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 12 Dec 2024
- Transactions
- 3
- Transaction value
- +$22,675
- Accepted by SEC
- 16 Dec 2024, 17:08
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 04 Oct 2024
- Transactions
- 1
- Transaction value
- +$8,436
- Accepted by SEC
- 08 Oct 2024, 17:58
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 12 Sep 2024
- Transactions
- 3
- Transaction value
- +$22,473
- Accepted by SEC
- 16 Sep 2024, 17:31
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 15 Aug 2024
- Transactions
- 9
- Transaction value
- -$8,072,614
- Accepted by SEC
- 19 Aug 2024, 16:01
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 05 Jul 2024
- Transactions
- 1
- Transaction value
- +$8,437
- Accepted by SEC
- 09 Jul 2024, 17:11
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 13 Jun 2024
- Transactions
- 3
- Transaction value
- +$22,224
- Accepted by SEC
- 17 Jun 2024, 18:54
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 22 May 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 23 May 2024, 18:45
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 14 May 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 May 2024, 15:36
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 09 May 2024
- Transactions
- 3
- Transaction value
- -$228,233
- Accepted by SEC
- 13 May 2024, 16:38
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 05 Apr 2024
- Transactions
- 1
- Transaction value
- +$8,438
- Accepted by SEC
- 09 Apr 2024, 16:56
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 14 Mar 2024
- Transactions
- 3
- Transaction value
- +$22,907
- Accepted by SEC
- 18 Mar 2024, 17:15
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 13 Feb 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Feb 2024, 19:21
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 05 Jan 2024
- Transactions
- 1
- Transaction value
- +$8,437
- Accepted by SEC
- 09 Jan 2024, 16:56
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 02 Jan 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Jan 2024, 16:10
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 14 Dec 2023
- Transactions
- 3
- Transaction value
- +$21,778
- Accepted by SEC
- 18 Dec 2023, 11:56
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 06 Oct 2023
- Transactions
- 1
- Transaction value
- +$8,126
- Accepted by SEC
- 10 Oct 2023, 08:48
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 14 Sep 2023
- Transactions
- 3
- Transaction value
- +$21,414
- Accepted by SEC
- 18 Sep 2023, 15:47
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 23 Aug 2023
- Transactions
- 7
- Transaction value
- -$6,954,161
- Accepted by SEC
- 25 Aug 2023, 16:02
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 11 Jul 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jul 2023, 17:34
- Role
- Director
- Next action
- Open filing details
3
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 11 Jul 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 Jul 2023, 17:26
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 07 Jul 2023
- Transactions
- 1
- Transaction value
- +$8,126
- Accepted by SEC
- 10 Jul 2023, 13:46
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 15 Jun 2023
- Transactions
- 3
- Transaction value
- +$21,169
- Accepted by SEC
- 20 Jun 2023, 16:02
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 09 May 2023
- Transactions
- 4
- Transaction value
- -$123,636
- Accepted by SEC
- 11 May 2023, 09:19
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 10 Apr 2023
- Transactions
- 1
- Transaction value
- +$8,124
- Accepted by SEC
- 12 Apr 2023, 15:37
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 16 Mar 2023
- Transactions
- 3
- Transaction value
- +$20,465
- Accepted by SEC
- 20 Mar 2023, 16:54
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 14 Feb 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Feb 2023, 15:56
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 06 Jan 2023
- Transactions
- 1
- Transaction value
- +$8,124
- Accepted by SEC
- 10 Jan 2023, 15:27
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 03 Jan 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2023, 15:20
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 15 Dec 2022
- Transactions
- 3
- Transaction value
- +$19,352
- Accepted by SEC
- 19 Dec 2022, 14:55
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 07 Oct 2022
- Transactions
- 1
- Transaction value
- +$8,126
- Accepted by SEC
- 11 Oct 2022, 16:45
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 15 Sep 2022
- Transactions
- 3
- Transaction value
- +$19,156
- Accepted by SEC
- 19 Sep 2022, 14:46
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 09 Aug 2022
- Transactions
- 4
- Transaction value
- -$6,646,299
- Accepted by SEC
- 11 Aug 2022, 16:09
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 08 Jul 2022
- Transactions
- 1
- Transaction value
- +$8,125
- Accepted by SEC
- 12 Jul 2022, 14:14
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 16 Jun 2022
- Transactions
- 3
- Transaction value
- +$18,905
- Accepted by SEC
- 21 Jun 2022, 14:01
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 10 May 2022
- Transactions
- 4
- Transaction value
- -$155,750
- Accepted by SEC
- 12 May 2022, 16:23
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 08 Apr 2022
- Transactions
- 1
- Transaction value
- +$8,126
- Accepted by SEC
- 12 Apr 2022, 14:53
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 11 Mar 2022
- Transactions
- 3
- Transaction value
- +$18,665
- Accepted by SEC
- 15 Mar 2022, 14:40
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 15 Feb 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Feb 2022, 11:04
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 07 Jan 2022
- Transactions
- 1
- Transaction value
- +$8,126
- Accepted by SEC
- 11 Jan 2022, 11:32
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 03 Jan 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2022, 15:44
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 16 Dec 2021
- Transactions
- 3
- Transaction value
- +$17,720
- Accepted by SEC
- 20 Dec 2021, 14:55
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 08 Oct 2021
- Transactions
- 1
- Transaction value
- +$7,814
- Accepted by SEC
- 13 Oct 2021, 18:47
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 16 Sep 2021
- Transactions
- 3
- Transaction value
- +$17,614
- Accepted by SEC
- 20 Sep 2021, 16:50
- Role
- Director
- Next action
- Open filing details
4
REGN
REGENERON PHARMACEUTICALS, INC.
- Report period
- 27 Aug 2021
- Transactions
- 13
- Transaction value
- -$9,164,756
- Accepted by SEC
- 31 Aug 2021, 16:03
- Role
- Director
- Next action
- Open filing details
4
SHW
SHERWIN WILLIAMS CO
- Report period
- 02 Jul 2021
- Transactions
- 1
- Transaction value
- +$7,812
- Accepted by SEC
- 07 Jul 2021, 13:53
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 17 Jun 2021
- Transactions
- 3
- Transaction value
- +$17,411
- Accepted by SEC
- 21 Jun 2021, 16:34
- Role
- Director
- Next action
- Open filing details
4
PRU
PRUDENTIAL FINANCIAL INC
- Report period
- 11 May 2021
- Transactions
- 4
- Transaction value
- -$307,701
- Accepted by SEC
- 13 May 2021, 16:56
- Role
- Director
- Next action
- Open filing details